Becton, Dickinson and Company (BD) reported a revenue increase of 1.6% for the first quarter of fiscal year 2026, totaling $5.252 billion, compared to $5.168 billion in the same period last year. The company's net income rose to $382 million, or $1.34 per diluted share, up from $303 million, or $1.04 per diluted share, in the prior year. This growth in profitability was attributed to improved operational efficiencies and a favorable foreign currency impact, despite facing challenges such as increased labor costs and tariffs.
In terms of operational changes, BD underwent a significant organizational restructuring effective October 1, 2025, dividing its operations into five distinct segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. Notably, the Life Sciences segment will be eliminated from future reporting following the spin-off of its Biosciences and Diagnostic Solutions business, which was combined with Waters Corporation on February 9, 2026. This strategic move is expected to enhance BD's focus on its core medical technology offerings.
The company reported a cash flow from operating activities of $657 million for the quarter, with total cash and equivalents, including short-term investments, amounting to approximately $1.035 billion as of December 31, 2025. BD continued to return value to shareholders, paying $299 million in dividends and repurchasing $250 million of its common stock during the period. The company plans to utilize approximately $2 billion from the cash distribution received from the Waters transaction for further share repurchases.
Geographically, BD's U.S. revenues increased by 2.6%, driven by strong sales in the Connected Care and BioPharma Systems segments. However, international revenues saw a slight increase of 0.2%, primarily due to declines in the BioPharma Systems and Life Sciences segments, with emerging markets, particularly China, facing challenges from volume-based procurement programs. The company is actively pursuing growth opportunities in emerging markets and aims to enhance its product offerings and operational efficiencies.
Looking ahead, BD remains focused on its strategic priorities of competing, innovating, and delivering value to customers. The company acknowledges potential risks, including macroeconomic factors, regulatory changes, and supply chain disruptions, which could impact future performance. Nonetheless, BD is committed to investing in research and development, geographic expansion, and new product initiatives to drive long-term growth and profitability.
About BECTON DICKINSON & CO
Becton, Dickinson and Company (BD) is a global medical technology firm specializing in medical supplies, devices, laboratory equipment, and diagnostic products. Its three main segments—BD Medical, BD Life Sciences, and BD Interventional—serve healthcare institutions, physicians, researchers, and pharmaceutical companies worldwide. BD focuses on improving medication management, patient safety, infection prevention, diagnostics, and surgical care through innovative, quality-driven solutions distributed via direct and independent channels.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.